Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Wednesday

Enlivex Therapeutics (NASDAQ:ENLV) will likely be issuing its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.0863) per share for the quarter.

Enlivex Therapeutics Price Performance

ENLV opened at $1.01 on Friday. Enlivex Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.10. The stock has a market capitalization of $239.75 million, a P/E ratio of -1.84 and a beta of 1.63. The business has a 50 day simple moving average of $0.96 and a 200-day simple moving average of $1.04.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENLV. XTX Topco Ltd lifted its holdings in shares of Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares in the last quarter. Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after buying an additional 52,553 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in Enlivex Therapeutics in the 3rd quarter valued at approximately $57,000. Invesco Ltd. acquired a new stake in Enlivex Therapeutics during the 4th quarter valued at $43,000. Finally, HRT Financial LP increased its position in Enlivex Therapeutics by 719.4% during the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after buying an additional 135,198 shares in the last quarter. Institutional investors and hedge funds own 1.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ENLV shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a report on Monday, November 24th. Wall Street Zen cut shares of Enlivex Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Finally, HC Wainwright boosted their price target on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $13.00.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.